Search
Search Results
-
Biomarker Defined Acute Optic Neuritis: A Review and Perspective
Purpose of reviewThis review provides a comprehensive summary of treatment options and management considerations for patients with acute inflammatory...
-
Targeting DORIS Remission and LLDAS in SLE: A Review
Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted...
-
Clinical research progress of novel biologics for the treatment of lupus nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the loss of immune tolerance. Lupus nephritis (LN) is one of the...
-
Role of telitacicept in the treatment of IgA nephropathy
IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and up to 40% of patients with IgAN develop end-stage renal...
-
Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy
IgA nephropathy, presently recognized as the foremost primary glomerular disorder, emerges as a principal contributor to renal failure globally, with...
-
Precision medicine in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease that has diverse clinical manifestations, ranging from restricted cutaneous involvement...
-
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
BackgroundTo determine the safety and efficacy of biological agents used in the treatment of systemic lupus erythematosus (SLE) in adults.
...
-
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus
Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic, inflammatory, heterogeneous autoimmune condition. This disease...
-
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)
Immunoglobulin A (IgA) vasculitis (IgAV, also known as Henoch-Schoenlein purpura, HSP) is the most common vasculitis of childhood. It usually...
-
Genetics of IgA nephrology: risks, mechanisms, and therapeutic targets
IgA nephropathy (IgAN) is a genetically complex multifactorial trait. Over the past decade, population-based genome-wide association studies (GWAS)...
-
Clinical advances in immunotherapy for immune-mediated glomerular diseases
Background and objectiveDue to the suboptimal therapeutic efficacy and potential adverse effects associated with traditional immunosuppressive...
-
Current treatment of systemic lupus erythematosus: a clinician's perspective
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Its variable course makes it difficult to standardize patient treatment. This...
-
Drugs in Development to Treat IgA Nephropathy
IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobulin (Ig) A antibodies....
-
Immunpathogenese des systemischen Lupus erythematodes
Insights into the immunopathogenesis of systemic lupus erythematosus (SLE) help to understand the complex disease patterns and to develop new...
-
Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis
BackgroundLupus nephritis (LN) affects a substantial number of the patients living with Systemic lupus erythematosus (SLE), representing a major...
-
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
The treat-to-target (T2T) concept has improved outcomes for patients with diabetes, hypertension and rheumatoid arthritis. This therapeutic strategy...
-
Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial
IgA nephropathy (IgAN), the most common form of primary glomerulonephritis, is mainly observed in young adults and children. Clinical and basic...
-
Current perspective of immunomodulators for lung transplant
Lung transplantation is an effective treatment option for selected patients suffering from end-stage lung disease. More intensive immunosuppression...
-
Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab
ObjectiveThis study aimed to determine the effect and safety of telitacicept, an antagonist of BLyS/APRIL-mediated B cell activation, in patients...
